Lutathera
What Lutathera is used for
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Lutathera
- Active substance
- lutetium (177Lu) oxodotreotide
- Disease area
- Neuroendocrine Tumors
- Medicine group
- Other therapeutic radiopharmaceuticals
- ATC code
- V10XX04
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lutathera used for?
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
What is the active substance in Lutathera?
Lutathera contains lutetium (177Lu) oxodotreotide.
Who makes Lutathera?
The EU marketing authorisation holder is Novartis Europharm Limited.
Is Lutathera an orphan medicine?
Yes. Lutathera is designated an orphan medicine in the EU, for a rare disease (Neuroendocrine Tumors).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU